Bulletin from the Annual General Meeting in Enzymatica AB (publ)
May 25 2016 - 7:34AM
Press release
Lund on 25 May
2016
Today on 25 May 2016, the Annual
General Meeting was held in Enzymatica AB (publ). A summary of the
resolutions adopted follows below. All resolutions were adopted
unanimously.
Appropriation of
profit/loss
The Annual General Meeting voted in favor of adopting the income
statement and the balance sheet of the group and parent company and
resolved to carry forward the funds available at the Annual General
Meeting and, consequently, resolved not to distribute any dividend
for the financial year 2015.
Discharge from liability for the
members of the Board of Directors and the CEO
The Annual General Meeting resolved to discharge the Board of
Directors and the CEO from liability for the financial year
2015.
Election of Board of Directors
and auditor
In accordance with the Nomination Committee's proposal, the Annual
General Meeting resolved to re-elect Lennart Nilsson, Marianne
Dicander Alexandersson, Hans Pihl, Nils Siegbahn, Monica Wallter,
Guðmundur Pálmason and Sigurgeir Guðlaugsson. Lennart Nilsson was
re-elected as the Chairman of the Board of Directors.
The Annual General Meeting further resolved to
appoint Ernst & Young AB as the company's auditor until the end
of the next Annual General Meeting.
Remuneration to the Board of
Directors
The Annual General Meeting resolved that remuneration for the Board
of Directors, excluding remuneration for committee work, shall be
paid with a total of SEK 900,000, of which SEK 180,000 is
remuneration for the Chairman of the Board of Directors and SEK
120,000 to every other member of the Board of Directors. In
addition, remuneration for work in the Audit Committee shall be
paid with SEK 50,000 to the Chairman of the Audit Committee and no
remuneration shall be paid to other members of the Audit Committee.
Further, no remuneration shall be paid for work in the Remuneration
Committee.
Principles for the Nomination
Committee
The Annual General Meeting resolved to adopt principles for the
Nomination Committee for upcoming elections and remuneration. The
Nomination Committee shall be comprised of representatives
appointed by the four largest shareholders as of 31 October,
together with the Chairman of the Board of Directors.
Guidelines for remuneration for
senior executives
The Annual General Meeting further resolved to adopt guidelines for
remuneration for senior executives, including a fixed salary and,
from time to time, variable payments for rewarding target-related
performances.
Authorisation of the Board of
Directors to issue new shares
The Annual General Meeting resolved to authorise the Board of
Directors until the next annual shareholders' meeting to, on one or
more occasions, resolve to increase the Company's share capital by
issue of no more than 17,500,000 new shares, with or without
deviation from the shareholders' preferential rights. The reason
for the board of directors' authorisation to deviate from the
shareholders' preferential rights is to enable the company's
possibilities to raise new capital and to take advantage of future
opportunities to attract new long-term owners of strategic
importance to the company, as well as to finance the Company's
growth strategy.
All resolutions by the Annual General Meeting were
adopted unanimously.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
PR Bulletin from AGM Eng final
160525
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#2015430
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024